Krempa David's Form 4 filing
Eton Pharmaceuticals, Inc.ETON · filed Jun 16, 2025
- Accession no.
- 0001437749-25-020518
- Filed
- Jun 16, 2025
- Trade date
- Jun 12-16, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $504.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Krempa DavidCIK 0001968254 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | Common Stock | SSaleDisposed | −16,977 | $14.92F1,F4 | −$253,296.84 | 629,669 | Direct | |
| Jun 13, 2025 | Common Stock | SSaleDisposed | −6,800 | $14.77F2,F4 | −$100,436 | 622,869 | Direct | |
| Jun 16, 2025 | Common Stock | SSaleDisposed | −10,223 | $14.73F3,F4 | −$150,584.79 | 612,646 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were sold in multiple trades at prices ranging from $14.77 to $14.98. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F2
The shares were sold in multiple trades at prices ranging from $14.75 to $14.81. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F3
The shares were sold in multiple trades at prices ranging from $14.50 to $14.79. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F4
The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 3 transactions in Table I.
Remarks
The Reporting Person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.